.
MergerLinks Header Logo

New Deal


Announced

Flerie Invest to acquire Cobra Biologics from Charles River for $52m.

Financials

Edit Data
Transaction Value£37m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Friendly

Single Bidder

Pharmaceuticals

Sweden

biopharmaceutical services

Majority

Venture Capital

Acquisition

Pending

Cross Border

Private

Private Equity

Synopsis

Edit

Flerie Invest, a venture capital firm, agreed to acquire Cobra Biologics, a provider of pharmaceutical and biotechnology research services, from Charles River, a pharmaceutical company, for $52m. “I look forward to working with the highly competent staff in Matfors to help grow innovative biotech companies, and to create security of supply of drugs and vaccines, and so be better prepared for future pandemics,” Ted Fjällman, Flerie Invest Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US